The Federal Trade Commission staff reviewing Roche’s plan to buy US-based gene therapy specialist Spark Therapeutics for $4.3 billion recommended that the deal be approved without requiring any asset sales, the Capitol Forum reported on Thursday.
Basel-based Roche, the biggest maker of cancer drugs, said in February that it would buy the US company, acquiring a portfolio that includes a blindness treatment that has US and European approval and other projects for neurodegenerative disorders like Huntington’s disease. One of its projects is a gene therapy treatment for hemophilia.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
